Ligufalimab

Phase 3Monoclonal antibody

UUniversity of Texas Southwestern Medical Center

Ligufalimab is one of 90 small molecule programs targeting Pembrolizumab. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PembrolizumabNot yet recruiting

Liver CancerRecruiting

PembrolizumabPhase 3

Not yet recruiting

Liver CancerPhase 2

Recruiting

Competition

Competitive Landscape

61 competitors in Liver Cancer

#DrugCompanyPhaseTrials

Blenoxane

Taxol

Idamycin

Opdivo

13 5

Eloxatin

Teva

Phase 3

8 6

Lenvima

Eisai

Phase 3

7 7

Rapamune

PPrism Pharmaceuticals

Glucophage

Alimta

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Not yet recruiting

Pembrolizumab

NCT07264075

Phase 2Recruiting

Liver Cancer

NCT06789848

Clinical

Trials by Indication[1]

Pembrolizumab1 trial

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

Not yet recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 3·NCT07264075·780 enrolled

Liver Cancer1 trial

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06789848·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ligufalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ligufalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ligufalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Texas Southwestern Medical Center

Ligufalimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Pembrolizumab1 trial

Liver Cancer1 trial

References

Drug Info

Quick Facts

Related News